Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B-Nagen is a brand name for nimesulide, a non-steroidal anti-inflammatory drug (NSAID) manufactured by ICA Pharmaceuticals. It functions as a preferential inhibitor of cyclooxygenase-2 (COX-2), an enzyme responsible for the synthesis of pro-inflammatory prostaglandins. By targeting COX-2 more selectively than COX-1, B-Nagen provides analgesic and anti-inflammatory effects while potentially reducing the risk of gastrointestinal side effects associated with non-selective NSAIDs. It is indicated for the treatment of acute pain and inflammatory conditions and is administered orally, typically in a 100 mg dosage form.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on B-Nagen.